Anti-Migraine Drugs Market size is estimated to reach $10.56bn by 2025, growing at a CAGR of 9.7% during the forecast period 2020-2025. Migraine is the severe headache caused on one-half of the head, which lasts for three hours to three days. The symptoms include vomiting, nausea, and sensitivity to light sound or smell. Anti-migraine drugs are the used to reduce the effect or intensity of the migraine headache. These anti-migraines include the drugs, which are used for the treatment of acute migraine symptoms and help in the prevention of migraine attacks. Globally about 15% of people are affected with migraine and increased usage of the anti-migraine drug is driving the market during the forecast period.
By Type – Segment Analysis
The global Anti-Migraine Drugs Market based on type has Triptans and Ergots. The Triptans segment includes Sumatriptan, Zolmitriptan, Rizatriptan, Frovatriptan and others. Triptans has registered for the highest market share in 2019. It is set to continue for the forecast period 2020-2025 owing to added advantage over Ergots. These drugs are to be consumed within 2 hours of the start of pain, for effective work. However, these are not good for people with high blood pressure, heart diseases, and pregnant women. The Triptans are available in the form of oral, injectable, nasal sprays and oral dissolving tablets. Ergots are also set to have positive growth as these drugs are used effectively even after two hours of the start of pain, and the ergots can be taken as nasal sprays, shots or get in through an IV.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=15694
Report Price: $ 4500 (Single User License)
By End-users – Segment Analysis
The End-users segment of Anti-Migraine Drugs Market has male and female. The female user’s segment registers for the highest market share in 2019 and is set to continue for the forecast period 2020-2025, owing to the increased migraine issue in the female population. According to a study conducted by different organizations, it is found that females need more meditation as they are more severe to the migraine than that of males. The male population using drugs for migraine are increasing but not as much as the female population. Increased research and development of new drugs are driving the growth of the market during the forecast period 2020-2025.
By Geography – Segment Analysis
Based on Geography the global Anti-Migraine Drugs Market is segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America holds the dominant share in the year 2019 and is set to have the fastest growth during the forecast period 2020-2025. This is owing to the increased awareness of migraine and its effects. Asia-Pacific is also set to have positive growth owing to the increased population facing migraine and rising awareness of the migraine in this region. The funding by the government and private sectors and increased health awareness among the people and increased research and developments being made for effective drugs is driving the market globally during the forecast period 2020-2025.
Drivers – Anti-Migraine Drugs Market
Increased awareness of Anti-migraine drug
The increase in awareness among the people about the usage of anti-migraine drugs and the growing migraine population are driving the market growth for anti-migraine drugs. Rapid penetration of medical facilities to the rural areas and increase in the development of new drugs by research and development activities are driving the market for the anti-migraine drug during the forecast period 2020-2025.
Talk to one of our sales representative about the full report by providing your details in the link below:
Challenges – Anti-Migraine Drugs Market
Side effects by intake of drugs
The anti-migraine drugs help the people to get rid of their pain, however, the high intake of drugs may cause side effects to the consumers, which is challenging the market during the forecast period 2020-2025.
Anti-Migraine Drugs Industry outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anti-Migraine Drugs Market. Key companies of this market are AstraZeneca plc, GlaxoSmithKline Plc, Pfizer Inc., Abbott Laboratories, Inc., Eisai, Inc., Impax Laboratories Inc., Allergan, Endo International Inc., Johnson and Johnson, Eli Lilly and others.
In June 2017, AstraZeneca had an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan, which is used for the treatment of migraine and cluster headaches, which worth is about $200 million.
In October 2019, ELI Lilly and Company has announced the REYVOW (lasmiditan), an oral medication for the acute treatment of migraine, in adults. This REYVOQ is only approved medicine in a new class of acute treatment for migraine.
Geographically, North America’s Anti-Migraine Drugs Market accounted for the highest revenue share in 2019 and it is poised to dominate during the forecast period 2020-2025 owing to the increased awareness and effects by migraine.
The rising population with migraine-related issues and increased research and development activities in the drug industry are driving the market during the forecast period 2020-2025.
Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Anti-Migraine Drugs Market report.
The key market players growing their market worldwide by marketing their drugs globally and providing qualified products at low cost by the manufacturers are driving the market.
Related Reports :
A. Drug Delivery Market
B. Lifestyle Drugs Market
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to email@example.com to discuss more about our consulting services.